Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Weight Change in Early RA & the Risk of Mortality

Arthritis & Rheumatology  |  December 20, 2017

The increased mortality risk for patients with rheumatoid arthritis (RA) compared with the general population may be attributable to altered immunity, medication side effects, systemic effects of inflammation, worsened physical function, accumulation of co-morbidities and excessive unhealthy behaviors, such as smoking. The contribution of metabolic and inflammatory factors (such as obesity) to RA etiology and outcomes has received increased attention recently. Several studies have investigated the effect of body mass index (BMI) on mortality in patients with RA. In RA cohorts, obesity has been associated with 34–67% decreased mortality compared with that in patients with a normal BMI.

Sparks et al set out to investigate whether weight change during the early RA period is associated with subsequent mortality and to evaluate whether there is an RA-specific effect. They investigated weight change during the early RA period, because this is the window of time during which weight change is most likely to be related to RA-specific processes.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Methods: The researchers identified patients with incident RA during the Nurses’ Health Study (1976–2016) and created a comparison cohort by matching each RA patient with up to 10 non-RA comparators by age and year of the RA diagnosis (index date). To capture weight change around the early RA period (“peri-RA/index”), they used weight measurements collected two to four years before and two to four years after the index date. They used Cox proportional hazard regression analysis to estimate hazard ratios (HRs) for mortality according to peri-RA/index weight change categories, separately in each cohort and in the combined cohorts, evaluating for an RA-specific effect.

Results: Among 121,701 women in the NHS, 902 patients with incident RA were identified and matched to 7,884 non-RA comparators. In the RA cohort, 371 deaths occurred during a mean follow-up of 17.0 years after the early RA period, and 2,303 deaths occurred in the comparison cohort during a mean follow-up of 18.4 years. Weight loss of more 30 lbs. during the peri-RA period had an HR for mortality of 2.78 (95% confidence interval [95% CI] 1.58–4.89) compared with stable weight; results in the comparison cohort were similar (HR 2.16, 95% CI 1.61–2.88). A weight gain of more than 30 lbs. had no association with mortality in patients with RA (HR 1.45, 95% CI 0.69–3.07) or comparators (HR 1.19, 95% CI 0.89–1.59). For mortality, there was no statistically significant interaction between RA/comparator status and weight change category (P=0.68).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & RheumatologyBMIbody mass index (BMI)mortalitymortality rateResearchRheumatoid Arthritis (RA)weight loss

Related Articles

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    May 13, 2021

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    COVID-19 Outcomes in Patients with Rheumatic Disease

    June 1, 2021

    In a study of patients with systemic autoimmune rheumatic diseases (ARDs) and matched comparators with COVID-19 but without systemic ARDs, D’Silva et al. found COVID-19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission and more than matched comparators.

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Studies Highlight Risk of Damage from Lupus Treatments

    April 20, 2017

    WASHINGTON, D.C.—Conference goers who braved the final day of the 2016 ACR/ARHP Annual Meeting were awarded for their stamina by learning about issues relating to the damage caused by systemic lupus erythematosus (SLE) during the session Systemic Lupus Erythematosus—Clinical Aspects and Treatment V: Damage and Morbidity. Minimizing Damage: Early Use of GC-Sparing Strategies Jayne Little,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences